Testing KRT-232 with a TKI for CML that didn’t respond
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies a new drug (KRT-232) combined with a standard CML “TKI” medicine to treat chronic myeloid leukemia (CML) that is resistant or not tolerated after at least one prior TKI. It may help people whose leukemia hasn’t controlled as expected on current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (18 or older).
- Your CML type must match the trial stage: chronic phase (CP) is for most arms; accelerated phase (AP) is for a specific arm only.
- Your leukemia tests must show TP53 “wild type,” and BCR-ABL positive, and must not have certain other CML stages listed for exclusion.
- You must have tried at least one prior TKI and had either relapse/poor response (resistant) or side effects that made you stop (intolerant).
- Your health status and organ function must be strong enough for study treatment (bone marrow, liver, and kidneys).
- You must NOT have the T315I mutation, and you must not have been treated with an MDM2-blocking drug before, and you must be able to tolerate your current TKI.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new targeted pill called TERN-701 for people with chronic myeloid leukemia (CML) that has not responded well to or caused side effects from other targeted therapies. The goal is to see if it is safe and effective.
This trial tests an experimental drug called TGRX-678 for people with a specific, more advanced stage of chronic myeloid leukemia (CML) called 'accelerated phase.' It’s for patients whose cancer has stopped responding to or who couldn't tolerate earlier targeted therapies (tyrosine kinase inhibitors).
This trial looks at how well children with chronic myeloid leukemia (CML) respond to standard “TKI” tablets when treatment starts. It uses genetic test results from diagnosis (DNA/RNA) to understand which children respond better and why.
This trial tests a combination of two drugs, dasatinib and ropeginterferon, for people newly diagnosed with chronic myeloid leukemia (CML) in its early chronic phase. The goal is to see if the combination works safely and helps control the disease.
This trial tests a new combination of three drugs (a third-generation TKI, azacitidine, and a Bcl-2 inhibitor) for people with chronic myeloid leukemia that has progressed to a more advanced phase (myeloid blast phase). The goal is to see if this combination is safe and effective.
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
Hear when a new Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.